FDA

Treatment of infections due to susceptible (β-lactamase-negative) strains causing the following syndromes:

• Infections of the ear, nose, and throat caused by Streptococcus spp. (α- and β-hemolytic strains), S. pneumoniae, Staphylococcus spp., or H. influenzae
• Infections of the genitourinary tract caused by E. coli, P. mirabilis, or E. faecalis.
  • Note: IDSA does not recommend empiric use due to higher resistance rates to E. coli and poor efficacy[8].
• Infections of the skin and skin structure caused by Streptococcus spp. (α- and β-hemolytic strains), Staphylococcus spp., or E. coli
• Infections of the lower respiratory tract caused by Streptococcus spp. (α- and β-hemolytic strains), S. pneumoniae, Staphylococcus spp., or H. influenzae
• Gonorrhea, acute uncomplicated (ano-genital and urethral infections) – due to N. gonorrhoeae (males and females). Note: The CDC does not recommend amoxicillin for the treatment of gonorrhea due to high rates of resistance.
• H. pylori eradication to reduce the risk of duodenal ulcer recurrence in combination with other antibiotics/medications.

Amoxicillin ER tablet (Moxatag™) has been discontinued for use in the U.S.

NON-FDA APPROVED USES

• Lyme disease
• Enterococcus infections
• Suppression therapy for prosthetic joint infections caused by streptococci, Enterococcus, C. acne
• Endocarditis prophylaxis
• Dental infections
• Low-risk penicillin allergies; challenge with oral penicillin "direct amoxicillin challenge"[16]